Full Press Release Details
ARCT-032 (CF) Phase 2 third cohort (28 days, 15 mg) generally safe and well tolerated
ARCT-032 permitted to proceed into 12-week Phase 2 study; dosing to begin H1 2026
Cash runway extended into Q2 2028
Investor conference call at 4:30 p.m. ET today
SAN DIEGO--(BUSINESS WIRE)--$ARCT#ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the fourth quarter and fiscal year 2025, and provided corporate updates.
“Arcturus continues to progress its rare disease therapeutic portfolio. We look forward to aligning with regulators on our clinical development strategy for the ornithine transcarbamylase (OTC) deficiency program, and to initiating our Phase 2, 12‑week cystic fibrosis (CF) study in the first half of 2026,” said Joseph Payne, President & CEO of Arcturus. “We remain firmly committed to advancing our once‑daily inhaled mRNA therapy for people with cystic fibrosis Class I mutations.”
Recent Corporate Highlights
Financial Results for the Fourth Quarter and Fiscal Year 2025
Revenue in conjunction with strategic alliances and collaborations:
Arcturus’ primary revenue streams include license fees, consulting and related technology transfer fees, reservation fees and collaborative payments received from research and development arrangements with pharmaceutical and biotechnology partners. Revenue for the fourth quarter and fiscal year 2025, was $7.2 million and $82.0 million, respectively, representing decreases of $15.6 million and $70.3 million compared to the same periods in 2024. These declines were driven by reductions in revenue from the CSL collaboration, reflecting lower supply agreement activity and a reduced number of development-based milestone achievements as KOSTAIVE® was commercialized.
Operating expenses:
Operating expenses for the fourth quarter and fiscal year 2025 amounted to $38.5 million and $158.3 million, respectively, representing decreases of $17.7 million and $89.7 million compared with the same periods in 2024.
Research and development expenses:
Research and development expenses consist primarily of external manufacturing costs, in vivo research studies and clinical trials performed by contract research organizations, clinical and regulatory consultants, personnel-related expenses, facility-related expenses and laboratory supplies related to conducting research and development activities. Research and development expenses were $24.5 million for the fourth quarter of 2025, compared with $43.8 million for the same period in 2024. The decrease was primarily driven by lower manufacturing costs for the LUNAR-COVID, LUNAR-FLU, and LUNAR-CF programs, as well as reduced clinical trial expenses for LUNAR-COVID and LUNAR-CF. Lower payroll and employee benefits further contributed to the decrease. These reductions were partially offset by higher facilities and equipment costs due to lease impairment in the current period.
Research and development expenses were $112.2 million for fiscal year 2025, compared with $195.2 million for fiscal year 2024. The decrease was primarily driven by lower manufacturing and clinical costs related to the LUNAR-COVID program, reflecting the program’s transition from a development program to the commercial phase. Additional decreases relate to lower manufacturing costs for the LUNAR-CF and LUNAR-FLU programs, as well as lower clinical costs associated with the LUNAR‑OTC program. These reductions were partially offset by higher clinical costs for Phase 2 of the LUNAR-CF program. Additional decreases resulted from lower payroll and benefits expenses following the operational restructuring.
General and Administrative Expenses:
General and administrative expenses primarily consist of salaries and related benefits for executive, administrative, legal and accounting functions and professional fees for legal and accounting services. General and administrative expenses for the fourth quarter of 2025 were $14.0 million compared with $12.4 million for the same period in 2024. The increase in fourth quarter expenses relates to the acceleration of employee stock options.
General and administrative expenses for fiscal year 2025 were $46.1 million compared with $52.8 million for fiscal year 2024. The decrease was primarily due to reduced share-based compensation expense as well as reduced payroll and benefits. We expect general and administrative expenses to continue to decrease slightly during the next twelve months driven by lower share-based compensation costs.
Net Loss:
For the fourth quarter of 2025, Arcturus reported a net loss of $29.1 million, or ($1.03) per diluted share, compared with a net loss of $30.0 million, or ($1.11) per diluted share for the same period in 2024. For fiscal year 2025, Arcturus reported a net loss of $65.8 million, or ($2.40) per diluted share, compared with a net loss of $80.9 million, or ($3.00) per diluted share for fiscal year 2024.
Cash Position and Balance Sheet:
Cash, cash equivalents and restricted cash were $232.8 million as of December 31, 2025, and $293.9 million as of December 31, 2024. Through disciplined execution and a strategic refocus on existing rare disease clinical programs in fiscal year 2025, Arcturus has extended its cash runway into the second quarter of 2028.
Arcturus Therapeutics Fourth Quarter and Fiscal Year 2025 Earnings Conference Call
Forward Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this press release, are forward-looking statements, including those regarding strategy, future operations, the likelihood of success of the Company’s pipeline (including ARCT-032 and ARCT-810) and partnered programs (including the COVID-19 and flu programs partnered with CSL Seqirus), the likelihood that clinical data, including interim data, will be predictive of future clinical results, the likelihood of and timing for achieving alignment with regulators on the clinical strategy for ARCT-810, plans to broaden the development strategy for ARCT-810, the timing for Type C regulatory meetings for ARCT-810 and feedback therefrom, the likelihood of initiation, and size, scope, and timing, of a Phase 2, 12-week study for ARCT-032, the ongoing development of a self-amplifying mRNA pandemic influenza vaccine under its contract with BARDA, the likelihood that general and administrative expenses will continue to decrease slightly, its current cash position and expected cash burn and runway, and the impact of general business and economic conditions. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements, including those discussed under the heading "Risk Factors" in Arcturus’ most recent Annual Report on Form 10-K, and in subsequent filings with, or submissions to, the SEC, which are available on the SEC’s website atwww.sec.gov. Except as otherwise required by law, Arcturus disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
About Arcturus
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration with CSL Seqirus, U.S. BARDA for pandemic flu and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA (siRNA), circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 500 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visitwww.ArcturusRx.com. Please connect with us onXandLinkedIn.
| ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIESCONSOLIDATED BALANCE SHEETS | ||||||||
| As of December 31, | ||||||||
| (in thousands, except per share data) | 2025 | 2024 | ||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 230,909 | $ | 237,028 | ||||
| Restricted cash | — | 55,000 | ||||||
| Accounts receivable | 5,564 | 3,974 | ||||||
| Prepaid expenses and other current assets | 4,973 | 9,977 | ||||||
| Total current assets | 241,446 | 305,979 | ||||||
| Property and equipment, net | 6,736 | 9,531 | ||||||
| Operating lease right-of-use asset | 21,081 | 26,674 | ||||||
| Non-current restricted cash | 1,885 | 1,885 | ||||||
| Total assets | $ | 271,148 | $ | 344,069 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 4,235 | $ | 7,194 | ||||
| Accrued liabilities | 23,898 | 38,781 | ||||||
| Deferred revenue | 8,246 | 19,514 | ||||||
| Total current liabilities | 36,379 | 65,489 | ||||||
| Deferred revenue, net of current portion | — | 12,604 | ||||||
| Operating lease liability, net of current portion | 20,784 | 24,998 | ||||||
| Total liabilities | 57,163 | 103,091 | ||||||
| Stockholders’ equity: | ||||||||
| Common stock: $0.001 par value; 60,000 shares authorized; issued and outstanding shares were 28,414 at December 31, 2025 and 27,000 at December 31, 2024 | 28 | 27 | ||||||
| Additional paid-in capital | 728,547 | 689,758 | ||||||
| Accumulated deficit | (514,590 | ) | (448,807 | ) | ||||
| Total stockholders’ equity | 213,985 | 240,978 | ||||||
| Total liabilities and stockholders’ equity | $ | 271,148 | $ | 344,069 |
| ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIESCONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | ||||||||||||
| Year Ended December 31, | ||||||||||||
| (in thousands, except per share data) | 2025 | 2024 | 2023 | |||||||||
| Revenue: | ||||||||||||
| Collaboration revenue | $ | 67,221 | $ | 138,389 | $ | 157,748 | ||||||
| Grant revenue | 14,810 | 13,921 | 9,051 | |||||||||
| Total revenue | 82,031 | 152,310 | 166,799 | |||||||||
| Operating expenses: | ||||||||||||
| Research and development, net | 112,212 | 195,156 | 192,133 | |||||||||
| General and administrative | 46,079 | 52,823 | 52,871 | |||||||||
| Total operating expenses | 158,291 | 247,979 | 245,004 | |||||||||
| Loss from operations | (76,260 | ) | (95,669 | ) | (78,205 | ) | ||||||
| Gain (loss) from foreign currency | 382 | (471 | ) | (229 | ) | |||||||
| Finance income, net | 10,095 | 15,195 | 16,591 | |||||||||
| Gain on debt extinguishment | — | — | 33,953 | |||||||||
| Net loss before income taxes | (65,783 | ) | (80,945 | ) | (27,890 | ) | ||||||
| (Benefit) provision for income taxes | — | (4 | ) | 1,835 | ||||||||
| Net loss | (65,783 | ) | (80,941 | ) | (29,725 | ) | ||||||
| Net loss per share, basic and diluted | $ | (2.40 | ) | $ | (3.00 | ) | $ | (1.12 | ) | |||
| Weighted-average shares outstanding, basic and diluted | 27,386 | 27,000 | 26,628 | |||||||||
| Comprehensive loss | $ | (65,783 | ) | $ | (80,941 | ) | $ | (29,725 | ) |
| ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIESCONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) | ||||||||
| Three Months Ended | ||||||||
| December 31, | ||||||||
| (in thousands, except per share data) | 2025 | 2024 | ||||||
| Revenue: | ||||||||
| Collaboration revenue | $ | 3,081 | $ | 21,000 | ||||
| Grant revenue | 4,115 | 1,766 | ||||||
| Total revenue | 7,196 | 22,766 | ||||||
| Operating expenses: | ||||||||
| Research and development, net | 24,476 | 43,780 | ||||||
| General and administrative | 14,027 | 12,380 | ||||||
| Total operating expenses | 38,503 | 56,160 | ||||||
| Loss from operations | (31,307 | ) | (33,394 | ) | ||||
| Gain from foreign currency | 701 | 171 | ||||||
| Finance income, net | 1,523 | 3,214 | ||||||
| Net loss before income taxes | (29,083 | ) | (30,009 | ) | ||||
| Benefit for income taxes | (4 | ) | (4 | ) | ||||
| Net loss | $ | (29,079 | ) | $ | (30,005 | ) | ||
| Net loss per share, basic and diluted | $ | (1.03 | ) | $ | (1.11 | ) | ||
| Weighted-average shares outstanding, basic and diluted | 28,112 | 27,000 | ||||||
| Comprehensive loss | $ | (29,079 | ) | $ | (30,005 | ) |